Pasithea Therapeutics (KTTA) Enterprise Value (2021 - 2024)
Historic Enterprise Value for Pasithea Therapeutics (KTTA) over the last 4 years, with Q3 2024 value amounting to -$9.4 million.
- Pasithea Therapeutics' Enterprise Value rose 5246.93% to -$9.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$9.4 million, marking a year-over-year increase of 5246.93%. This contributed to the annual value of -$16.3 million for FY2023, which is 5064.34% up from last year.
- Per Pasithea Therapeutics' latest filing, its Enterprise Value stood at -$9.4 million for Q3 2024, which was up 5246.93% from -$8.0 million recorded in Q2 2024.
- Over the past 5 years, Pasithea Therapeutics' Enterprise Value peaked at -$8.0 million during Q2 2024, and registered a low of -$53.0 million during Q4 2021.
- Moreover, its 4-year median value for Enterprise Value was -$26.8 million (2023), whereas its average is -$28.4 million.
- Its Enterprise Value has fluctuated over the past 5 years, first plummeted by 10616.38% in 2022, then surged by 7011.59% in 2024.
- Quarter analysis of 4 years shows Pasithea Therapeutics' Enterprise Value stood at -$53.0 million in 2021, then soared by 37.53% to -$33.1 million in 2022, then soared by 50.64% to -$16.3 million in 2023, then surged by 42.68% to -$9.4 million in 2024.
- Its Enterprise Value was -$9.4 million in Q3 2024, compared to -$8.0 million in Q2 2024 and -$12.0 million in Q1 2024.